Introduction
Metastasis is a complex multistep process, during which tumor cells must proliferate, invade the host stroma, enter the circulation, survive and arrest in a distant organ's capillary bed, extravasate into the organ parenchyma, and proliferate again [1, 2] . Proteolytic degradation of the extracellular matrix (ECM) is an important part of the process, and several classes of enzymes have been implicated, including matrix metalloproteinases (MMPs) [3] , serine proteinases [4] , cysteine proteinases [5] , and aminopeptidases [6] . These enzymes are not only secreted by a variety of metastatic tumor cells but also by normal cells under certain conditions. Aminopeptidase N is a Zn 2 +-dependent exopeptidase that is anchored to the plasma membrane by its N-terminal segment and acts as an ectoenzyme. It has been postulated that this enzyme has multiple functions, including hydrolytic inactivation of such regulatory peptides as enkephalins. The aminopeptidase N is identical to cell surface antigen CD13, which is produced by myeloid cells and by many other types of cells [7] . For example aminopeptidase N is expressed on epithelial cells of the gut and possibly utilized as an infection receptor by enteropathogenic coronavirus, a transmissible virus that causes gastroenteritis [8, 9] . The plasma membranes of several human and rodent tumor cells have high levels of neutral aminopeptidase activity [10, 11] . We have previously reported that bestatin, a potent inhibitor of aminopeptidases, suppresses degradation and invasion of the ECM by tumor cells [6, 12] . We have also shown that anti-aminopeptidase N/CD13 monoclonai antibody, capable of inhibiting aminopeptidase, can suppress degradation and invasion of the ECM by tumor cells [13] . These findings have suggested the possible involvement of aminopeptidase N/CD13 in the molecular mechanisms of tumor cell invasion.
In this study, we engineered human melanoma A375M cells to overexpress aminopeptidase N/CD13 and studied the cells' invasive behavior. We show here that a high expression of aminopeptidase N/CD13 in human melanoma cells significantly enhanced their ability to degrade and invade the ECM and hence increased their lung colonising potential.
Materials and methods

Cells
The human malignant melanoma cell line A375M was kindly provided by Dr I. J. Fidler (M. D. Anderson Cancer Center, Houston, TX). Rat lung endothelial cell clone-4 (RLE-4) was established as described previously [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . These cells were maintained as monolayer cultures in RPMI-1640 containing 10% fetal bovine serum (FBS).
Animals
Pathogen-free male athymic KSN nu/nu mice (6 weeks old) were purchased from the Shizuoka Laboratory Animal Center (Hamamatsu, Japan). The mice were housed in a barrier facility and maintained under laminar air-flow conditions.
Transfection of A375M melanoma cells with aminopeptidase N/CD13 expression vectors
A eukaryotic plasmid expression vector containing the full-length aminopeptidase N/CD13 complement DNA (pZipSV(x)neoCD13) was kindly provided by Dr T. . pZipSV(x)neoCD13 and control pZipSV(x)neo vectors were transfected by the electroporation technique into A375M melanoma cells and those resistant to 1 mg/ml G-418 were selected. The transfectants were grown and maintained in RPMI-1640 supplemented with 10% FBS and 1 mg/ml G-418. We took the utmost care to freeze and thaw the established transfectants and minimize passaging of the cells before their characterization in vitro and in vivo. The presence of the plasmids in the transfectants were determined by Southern blotting of the genomic DNA with a 2.5 kbp Bam HI fragment of the CD13 cDNA.
Aminopeptidase assay
Aminopeptidase activity was assayed by measuring the amount of 7-amino-4-methylcoumarin (AMC) liberated from amino acid-4-methylcoumarin-7-amide (amino acid-MCA, Peptide Institute, Osaka, Japan) by cell-associated aminopeptidases. A mixture containing 0.1 mM amino acid-MCA and 5 x 103 tumor cells in 200 pl of Hank's buffer solution was placed in each well of a 96-well microplate and incubated for 2 h at 37°C. Every 30 min, the incubation mixture was mixed with 50/A of 0.1 M ethylenediaminetetraacetic acid (EDTA) to terminate the reaction and the AMC level was determined with a Baxter Fluorescence Concentration Analyzer (excitation, 365 nm; emission, 450nm. Baxter, Mandolin, IL). The activity was calculated from the amount of AMC formed by the tumor cells added [12] .
Flow cytometric analysis
Tumor cells were harvested from subconfluent cultures, washed with phosphate-buffered saline (PBS), and suspended in PBS containing 0.2% FBS and 0.1% NaN 3. The cells were then incubated with FITCconjugated monoclonal antibodies (mAb) specific for CD13/aminopeptidase N (Silenus, Howston, Australia) for 30 min at 4°C and washed three times with PBS. FITC-labeled cells were analyzed using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
Invasion assay
The invasive activity of tumor cells was assayed using Transwell cell culture chambers according to the method previously reported [15] . Briefly, the lower surface of polyvinylpyrrolidone-free polycarbonate filters with 8.0 #m pores (Nucleopore, Pleasanton CA.) were precoated with 0.1 mg/ml of fibronectin or laminin in PBS (5 #g/filter). Matrigel was diluted to l mg/ml with cold PBS, applied to the upper surfaces of the filters (10#g/filter), and dried at room temperature under a hood. These filters were designated Matrigel/fibronectin-and Matrigel/ laminin-coated filters. The coated filters were extensively washed in PBS and then dried immediately before use. Tumor cells were harvested with 1 mM EDTA in PBS, washed three times with serum-free Eagle's minimum essential medium (EMEM), and then resuspended to a final concentration of 10 6 cells/ml in EMEM containing 0.1% bovine serum albumin (BSA). Cell suspensions (100#1 each) were added to the upper compartment and incubated for a certain period at 37°C in a 5% CO2 atmosphere. The filters were fixed with methanol and stained with hematoxylin and eosin. The cells on the upper surface of the filter were removed by wiping with cotton swabs. The cells that had invaded various areas of the lower surface were manually counted under a microscope. Each assay was performed in triplicate.
Tumor cell migration along a gradient of substratumbound fibronectin or laminin was assayed in Transwell cell culture chambers, as previously reported 1, 15] . The filters were precoated with 5pg of fibronectin or laminin on the lower surface and dried at room temperature. The subsequent procedures were the same as those used for the invasion assay.
Cell adhesion assay
The cell attachment assay was carried out by the method of Saiki et al. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Tumor cells in the exponential growth phase were washed twice in PBS, harvested by a brief treatment with 1 mM EDTA in PBS, and resuspended in cold serum-free EMEM to form a single cell suspension. Matrigel was diluted to 1 mg/ml with cold PBS, applied to microculture wells (10/tg/well), and dried at room temperature under a hood. Five/tg/ml of fibronectin, laminin, or 10 mg/ml of bovine serum albumin (BSA) were added to microculture wells and incubated at 37°C for 2 h. The tumor cells (2 × 104) were added to the microculture wells and incubated for 1 h at 37°C. The wells were washed three times with PBS to remove unattached cells and cells attached to Matrigel were evaluated using the MTT assay. Two hundred microliters of RPMI-1640 with 5% FCS and 10/d per well of MTT solution (5 mg/ml) were added to each well and incubated at 37°C. After 4h incubation the supernatants were removed carefully with micropipettes and 100#1 of DMSO was added to dissolve the MTT-formazan product. The absorbance of the solutions in each well was monitored at 540 nm. The cells attached to fibronectin, laminin or BSA coated microculture wells were stained with 0.5% crystal violet in 20% methanol for 30min. After washing with water, the number of residual stained cells was estimated by measuring absorbance at 600 nm.
collagenolytic activity was calculated from the radioactivity in the supernatant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Assay for 9elatinolytic enzyme production
Cells cultured in a 100-mm dish were washed three times with PBS and once with serum-free EMEM; they were then refed with 5ml of serum-free DMEM/F-12. After a 48 h incubation, the supernatants were collected, sequentially centrifuged at 900 0 for 5 min and at 10000 0 for 30 rain at 4°C. Gelatinolytic enzymes secreted into the supernatants were identified and quantified by zymography, as described [16] .
Assays for tumorigenicity and lun9 colon&ation potential
Six-week-old nude mice were given 500/~g injections of rabbit anti-asialo GM-1 antibody (Wako, Tokyo, Japan) in the lateral tail veins on the day before cell inoculation. Cultured tumor cells were harvested from subconfluent cultures by a brief incubation with 0.05 % EDTA. The flasks were sharply tapped to dislodge the cells, which were then washed in medium with 10% FBS, gently pipetted, and resuspended in PBS. Cells (2 x 105) suspended in 200/tl of PBS were injected into the lateral tail vein of each mouse. Seven weeks later, the mice were anesthetized and killed by bleeding. The lungs were removed and the numbers of peripheral tumor colonies in the lungs were determined by blinded observers using a dissecting microscope. To assess tumorigenicity of the transfectants, 1 × 106 cells suspended in 100 pl of PBS were injected s.c. into a nude mouse. The tumor volume was estimated from three-dimensional measurements using calipers.
Statistical analysis
The significance of differences between groups was determined by Student's two-tailed t-test or the two-tailed Mann-Whitney U-test. Correlation coefficients were determined by Spearman or Pearson.
Assay.for type IV collagenolysis
Each well of a 96-well tissue culture plate was coated with [3HI-labeled type IV collagen film (3 × 105 cpm/ 1.6~g/ml). Prior to use, a 100/d aliquot of a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 nutrient medium (DMEM/F12 medium) was added over the dried type IV collagen film and incubated for 3h at 37°C. Tumor cells (5 × 105 ) suspended in 200#1 of DMEM/F12 medium were added into each type IV collagen-precoated well. After a 24h incubation, the culture supernatant was removed and undigested materials were precipitated by mixing with 100 pl of ice-cold 50% trichloroacetic acid and centrifuged at 18000g for 10min. Type IV
Results
Transfection of A375M cells with aminopeptidase N/ CD13 cDNA
The expression vector pZipSV(x)neoCD 13 and control pZipSV(x)neo were introduced into A375M malignant melanoma cells. These cells were cultured in the presence of 1 mg/ml of G-418 for 20 days. Several hundred clones resistant to G-418 were obtained. These transfectants were mixed and maintained in the presence of 1 mg/ml of G-418. expressed moderate levels of aminopeptidase N/CD 13 on their surfaces. The cells that were transfected with pZipSV(x)neoCD13 vectors expressed significantly higher levels of aminopeptidase N than the parental A375M cells ( Figure 1A and B). Aminopeptidase N expression level was unaffected by the transfection with control pZipSV(x)neo vectors ( Figure 1A and C) . We did not observe any differences in the growth characteristics of these cells. We examined aminopeptidase activity in the transfectants by measuring AMC liberated from alanine-MCA, arginine-MCA, and glutamic acid-MCA. As shown in Table 1 , the cells demonstrated hydrolyzing activities against Ala-MCA, Arg-MCA, and Glu-MCA. However, AIa-MCA was the preferable substrate for aminopeptidases produced by the parental cells and transfectants. This substrate specificity pattern is typical of aminopeptidase N. The pZipSV(x)neoCD13 transfectants produced higher levels of the aminopeptidase N activity than the parental or control vector-transfected cells. The aminopeptidase activity levels in these cells were consistent with their CD13 antigen expression levels measured by flow-cytometry. We selected 5 clones transfected with pZipSV(x)neoCD13 (two strongly positive, two with intermediate levels and one weakly positive) (Figure 1 E, F and G) and one clone transfected with pZipSV(x)neo alone (base level) using flow cytometry ( Figure 1H ). The expression levels of CD13 in these cells are summarized in Figure 3 . (a parental A375M; b control vector transfected cells; c CD13 transfected cells; d control vector transfected clone; e--i CD13 transfected clones). Clones e, f and g have one copy of CD13 cDNA plasmid; clones h and i have two copies. These clones were maintained in 1 mg/ml of G-418. 
Invasive ability modified by aminopeptidase N/CD13 expression
The invasive capacity of pZipSV(x)neoCD 13-transfected cells was measured using Matrigel-coated Transwell culture plates. The transfectants were incubated for 8 h at 37°C in the upper compartment of the Transwell chambers, which were precoated with reconstituted Matrigel. The representative results from three independent experiments are shown in Figure 2A . The abilities of the aminopeptidase N/CD 13 transfectants to invade into Matrigel/laminin-or Matrigel/fibronectincoated filters were significantly higher than those of the parental or control cells (P<0.01). There was no difference, however, in invasiveness between the parental A375M and control vector-transfected cells. These data suggest that high expression of aminopeptidase N/CD13 in the melanoma cells led to enhanced invasiveness. Next, the migratory potentials of these cells were compared. To assess haptotactic migration, tumor cells were seeded into the upper compartment of a Transwell cell culture chamber with a filter precoated with 5 ~g of fibronectin or 5/~g of laminin on the lower surface. The number of cells that migrated to the lower surface was determined after a 4 h incubation ( Figure 2B ). Migratory activity did not differ amongst these cells. The results indicated that the higher invasive capacity obtained by the transfectants was not due to enhanced cell motility.
To further investigate the relationship between invasive potential and aminopeptidase N/CD13 expression, we simultaneously assayed parental A375M cells, mixed cell lines and six clones transfected with pZipSV(x)neoCD 13 or pZipSV(x)neo for invasive, migratory activity and CD13 expression. Since the cells cloned from the parental lines and transfectants showed different migratory activities because of their clonal heterogeneity, we calculated an index showing The cells attached to fibronectin, laminin and BSA were stained with crystal violet. * P <0.01.
relative invasiveness versus migratory activity. This index was plotted against the aminopeptidase N/CD 13 expression level measured by flow cytometry (Figure 3 ). There was a good correlation between this index and aminopeptidase N/CD13 expression levels. The correlation coefficients were 0.891, P = 0.0012 by Pearson and 0.801, P = 0.0041 by Spearman analysis.
Cell attachment
The tumor cell invasion process consists of three important steps: cell adhesion, migration and degradation of the ECM. Therefore, we examined the adhesion of these transfectants to Matrigel and such ECM components as laminin and fibronectin and to BSA as a nonspecific control protein. During the first 2h incubation, both the parental cells and the transfectants attached to Matrigel-, fibronectin-, laminin-and BSA-coated plates (Table 2) . Matrigel and fibronectin promoted cell adhesion, whereas laminin did little to enhance adhesion. The extent of adhesion to fibronectin did not vary among the parental cells and transfectants, whereas the CD13 transfectants showed increased adhesion to Matrigel compared with the parental and control vectortransfected cells. However the adhesion was not inhibited by the aminopeptidase inhibitor, bestatin.
Deyradation of the extracellular matrix
Degradation of the ECM during tumor invasion involves a number of enzymes including matrix metalloproteinases, plasminogen activators and other proteinases. Therefore, we determined whether the enhancement ofinvasive capacity by CD13 expression was associated with the increased activity to degrade type IV collagen and the ECM. The cells were incubated for 24 h in wells precoated with [3H]-labeled type IV collagen. The CD13-transfected A375M cells showed the highest levels of type IV collagen degradation, with a significance at P < 0.001 (Figure 4) . We then tried to determine whether the degradation of type IV collagen was due to enhanced secretion and activation of gelatinolytic metalloproteinases. To do this, we analyzed the cell culture supernatants by gelatin zymography and found that aminopeptidase N/CD13 expression did not correlate with secretion and activation of gelatinolytic metalloproteinases including MMP-2, MMP-3 and MMP-9 (data not shown).
Lun9 colonizin9 potential
Effects of the increased aminopeptidase N expression on tumorigenicity and lung colonizing potential were examined using KSN nude mice. Tumor cells were injected s.c.
(1 x l0 6 cells/mouse), and the mice were observed for the formation of tumors over 7 weeks. Expression of aminopeptidase N/CD13 had no detectable effect on the tumorigenicity and the growth rate of primary s.c. tumors (data not shown).
We then verified the lung colonizing potential of these cells using experimental metastasis models. The numbers of lung colonies formed 51 days after i.v. injection of 2x 10 5 cells are shown in Figure 5 . Aminopeptidase N/CD13-transfectants showed significant increases in the number of tumor nodules compared with the control and parental cells. The results were correlated with the increased invasive capacity and the ECM-degrading activity of the transfectants. 
Discussion
In the present study, we introduced eukaryotic expression vectors containing the full length cDNA of aminopeptidase N/CD 13 into A375M melanoma cells that had a lower level of aminopeptidase N/CD13 than other highly metastatic cell lines. The aminopeptidase N/CD 13 transfectants expressed high levels of the cell surface CD13 antigen and exhibited enhanced aminopeptidase activities. The high expression of aminopeptidase N led to increases in the invasive ability and type 1V collagenolytic activity of the melanoma cells. The transfectants did not show altered phenotypes in terms of growth, adhesion to and migration towards ECM components such as fibronectin and laminin. However, the transfectants that expressed high levels of aminopeptidase N/CD13 demonstrated augmented lung colony formation after i.v. injection in nude mice. To ascertain that these phenomena were not restricted to one melanoma cell line, we transfected another melanoma cell line, A2058, with aminopeptidase N/CD 13 cDNA and found that the A2058 transfectants also expressed higher levels of aminopeptidase N/CD 13 and increased activities of type IV collagenolysis and invasion as well as experimental lung metastasis (data not shown). These results confirmed that melanoma cells could utilize aminopeptidase N/CD13 in proteolytic degradation of the ECM.
Bestatin, an aminopeptidase inhibitor, is known to be a low-molecular-weight immunostimulant and has been shown to inhibit metastasis in P388 leukemia [17] and B16 melanoma cells [18] in mice. We have found that inhibitors of aminopeptidase N, such as bestatin and actinonin, significantly inhibited the invasion of murine and human metastatic tumor cells into reconstituted basement membranes and also inhibited their type IV collagenolytic activity [6, 12] . Anti-aminopeptidase N/CD13 monoclonal antibody, which blocks the aminopeptidase N activity, had similar effects on several human tumor cell lines [13] .
Menrad et al. [19] reported that aminopeptidase N was expressed on malignant melanoma cells but was absent from normal melanocytes. A high level of plasma membrane-associated aminopeptidase activity was observed in rat mammary adenocarcinoma cells which spontaneously metastasize from the mammary fat-pad to lymph nodes and lungs [11] . Therefore, the membrane-associated aminopeptidase N is probably involved in invasion and metastasis of a variety of tumor cells. Aminopeptidase N/CD 13 is also expressed by macrophages and fibroblasts that exhibit high motility in solid tissues [20] . Thus the enzyme may also play an role in the degradation and invasion of the ECM by these normal cells.
The activity of metalloproteinases in proteolysis of basement membrane collagen type IV was first reported by Liotta et al. [21] . A good correlation between type IV collagenolytic activity and metastatic potential has been found using a variety of human and animal tumor cell lines [3, 14] A significant increase in collagenolytic activity was also attained by high expression of aminopeptidase N/CD13.
Aminopeptidase N is a Zn2+-dependent ectoenzyme that is anchored to the plasma membrane. Localization of the enzyme was observed in the invasion edge of SN12M renal carcinoma cells attached to Matrigel [13] . The enzyme has broad specificity and is able to remove N-terminal residues from almost all unsubstituted oligopeptides except N-terminal proline or glutamic acid. Thus, aminopeptidase activity may contribute to the cascade of tumor invasion mechanisms by hydrolyzing ECM components already cleaved by other endoproteinases, such as plasmin or type IV collagenases/gelatinases [22] . Menrad et al. [19] found that human placental aminopeptidase N digested a component of the basement membrane Matrigel that may contain latent forms of type IV collagenases. Our previous experiments using zymography showed that treating the tumor cells with bestatin caused the active form of type IV collagenase to disappear [12] . These results led us to assume that the plasma membrane aminopeptidase N/CD 13 may have a role in activating type IV procollagenases. However, in our present study, gelatinase A/Mr 72000 type IV collagenase activation was not observed in the transfectants of aminopeptidase N/CD13 (data not shown). Details concerning the possible targets for aminopeptidase N and the ECM degradation cascade remain to be determined.
We have shown that a high expression of aminopeptidase N/CD13 in A375M melanoma cells promoted invasive capacity and type IV collagenolytic activity. These data imply that the cell surface aminopeptidase N could be a target for detection of malignant melanoma cells and for the reversal of their invasive phenotype.
